BCYC
BICYCLE THERAPEUTICS PLCCompany Information
- Company Name
- BICYCLE THERAPEUTICS PLC
- CIK
- CIK0001761612
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BCYC: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BCYC
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-16
- Last sale
- 2026-07-06
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 37,375
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 33,403,724
- Shares outstanding
- 69,804,828
- Ownership
- 47.85%
Earnings Market Reaction
- Filing date
- 2026-07-30
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 510 | 559 | 628 | 648 | 721 | 793 | 880 | 891 | 961 | 457 | 526 | 572 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | 0 | - | - | 0 | - | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 18 | 19 | 19 | 23 | 22 | 17 | 13 | 17 | 20 | 20 | 11 | 14 | ||||||
| Assets Current | 575 | 619 | 683 | 739 | 804 | 856 | 929 | 966 | 1,028 | 516 | 562 | 603 | ||||||
| Property Plant And Equipment Net | 5 | 6 | 6 | 7 | 8 | 9 | 10 | 12 | 12 | 13 | 15 | 16 | ||||||
| Operating Lease Right Of Use Asset | 14 | 15 | 16 | 5 | 6 | 7 | 8 | 9 | 11 | 12 | 13 | 15 | ||||||
| Other Assets Noncurrent | 13 | 13 | 13 | 14 | 14 | 12 | 11 | 10 | 7 | 6 | 6 | 5 | ||||||
| Assets | 607 | 652 | 718 | 764 | 832 | 884 | 957 | 997 | 1,057 | 547 | 595 | 639 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 6 | 6 | 10 | 13 | 18 | 11 | 16 | 6 | 7 | 7 | 13 | 8 | ||||||
| Accrued Liabilities Current | 39 | 40 | 44 | 44 | 45 | 34 | 41 | 39 | 28 | 26 | 32 | 34 | ||||||
| Deferred Revenue Current | 3 | 3 | 3 | 12 | 15 | 13 | 10 | 11 | 12 | 16 | 25 | 27 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | - | - | 22 | - | - | - | ||||||
| Liabilities Current | 48 | 49 | 57 | 69 | 77 | 58 | 67 | 56 | 70 | 50 | 70 | 70 | ||||||
| Long Term Debt Noncurrent | - | - | - | - | - | - | - | - | 9 | 31 | 31 | 31 | ||||||
| Operating Lease Liability Noncurrent | 14 | 14 | 14 | 1 | 2 | 3 | 4 | 6 | 7 | 8 | 9 | 10 | ||||||
| Deferred Revenue Noncurrent | 34 | 34 | 36 | 74 | 83 | 82 | 91 | 98 | 94 | 98 | 110 | 108 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 5 | 5 | 5 | 4 | ||||||
| Liabilities | 96 | 98 | 108 | 145 | 163 | 144 | 164 | 166 | 184 | 191 | 224 | 223 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital | 1,526 | 1,519 | 1,512 | 1,501 | 1,492 | 1,482 | 1,473 | 1,462 | 1,452 | 895 | 883 | 875 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -5 | -5 | -4 | -3 | -3 | -1 | 0 | -3 | -1 | -1 | -1 | 3 | ||||||
| Retained Earnings Accumulated Deficit | -1,011 | -961 | -900 | -880 | -820 | -742 | -681 | -629 | -578 | -538 | -512 | -463 | ||||||
| Stockholders Equity | 510 | 554 | 610 | 618 | 669 | 740 | 793 | 831 | 874 | 356 | 371 | 416 | ||||||
| Liabilities And Stockholders Equity | 607 | 652 | 718 | 764 | 832 | 884 | 957 | 997 | 1,057 | 547 | 595 | 639 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 163 | 163 | 160 | 160 | 160 | 159 | 156 | 156 | 154 | 62 | 60 | 60 | ||||||
| Common Stock Shares Issued | 70 | 70 | 69 | 69 | 69 | 69 | 69 | 69 | 69 | 43 | 42 | 42 | ||||||
| Shares Outstanding | 70 | 70 | 69 | 69 | 69 | 69 | 69 | 69 | 69 | 43 | 42 | 42 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBICYCLE THERAPEUTICS PLC (BCYC) — SEC Financial Statements & Analysis
BICYCLE THERAPEUTICS PLC (BCYC) is a pharmaceutical preparations company, incorporated in X0. BICYCLE THERAPEUTICS PLC trades on Nasdaq as: BCYC. BICYCLE THERAPEUTICS PLC (BCYC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, BICYCLE THERAPEUTICS PLC carries a market cap of $295.97M, a P/E ratio of -1.55x, a P/B ratio of 0.58x, a P/S ratio of 4.84x, an enterprise value of $-214.14M, and an EV/EBITDA multiple of 1.04x. On profitability, it posts a gross margin of 107.87%, an operating margin of -343.60%, a net margin of -311.11%, a Return on Equity (ROE) of -32.30%, and a Return on Assets (ROA) of -26.47%. Per share, it reports EPS of $-2.73, diluted EPS of $-2.73, free cash flow per share of $-2.98, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 217.44% year-over-year, net income growth of -21.43% year-over-year, and EPS growth of -22.06% year-over-year. On the balance sheet, it maintains a current ratio of 12.08x, a quick ratio of 11.70x, working capital of $527.60M, a debt-to-equity ratio of 0.19x, a debt ratio of 0.16, an interest coverage ratio of -1089.64x, free cash flow of $-208.28M (TTM), and net debt of $-510.11M. Figures sourced from SEC EDGAR.
- Market Cap
- $295.97M
- P/E TTM
- -1.55x
- EPS TTM
- $-2.73
- P/B TTM
- 0.58x
- ROE TTM
- -32.30%
- ROA TTM
- -26.47%
- Debt To Equity
- 0.19x
- Free Cash Flow TTM
- $-208.28M
- Net Revenue TTM Growth 1Y
- 217.44%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BICYCLE THERAPEUTICS PLC in?
BICYCLE THERAPEUTICS PLC (BCYC) operates in the Pharmaceutical Preparations industry.
What exchange does BCYC trade on?
BICYCLE THERAPEUTICS PLC (BCYC) trades on the Nasdaq.
Where is BICYCLE THERAPEUTICS PLC incorporated?
BICYCLE THERAPEUTICS PLC is incorporated in United Kingdom.
When was BICYCLE THERAPEUTICS PLC (BCYC)'s most recent SEC filing?
BICYCLE THERAPEUTICS PLC (BCYC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30.
What is BCYC's market cap?
BICYCLE THERAPEUTICS PLC (BCYC) has a market capitalization of $295.97M as of 2026-06-30.
What is BCYC's EPS (earnings per share)?
BICYCLE THERAPEUTICS PLC (BCYC)'s trailing twelve month EPS is $-2.73 as of 2026-06-30.
What is BCYC's ROE (return on equity)?
BICYCLE THERAPEUTICS PLC (BCYC)'s trailing twelve month Return on Equity (ROE) is -32.30% as of 2026-06-30.
What is BCYC's ROA (return on assets)?
BICYCLE THERAPEUTICS PLC (BCYC)'s trailing twelve month Return on Assets (ROA) is -26.47% as of 2026-06-30.
What is BCYC's EV/EBITDA?
BICYCLE THERAPEUTICS PLC (BCYC)'s trailing twelve month EV/EBITDA is 1.04x as of 2026-06-30.